Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Core Insights - Myriad Genetics and Lumea Inc. have entered into a collaboration to integrate Myriad's molecular diagnostic tests into Lumea's digital pathology platform, BxLink™ [1][2] Company Overview - Myriad Genetics specializes in genetic and genomic tumor testing and precision medicine, focusing on improving health and well-being through advanced genetic tests [5] - Lumea is a leader in clinical digital pathology, known for its innovative tissue-handling technology and AI-driven workflows, enhancing efficiency and quality in cancer diagnostics [4] Collaboration Details - The integration will allow healthcare providers to electronically order and track Prolaris and MyRisk tests, aiming to deliver results in under 10 days after specimen collection [2][3] - This collaboration is expected to reduce manual processes, thereby minimizing errors and improving the workflow for clinicians [2][3] Clinical Impact - Prolaris and MyRisk tests provide critical insights for cancer treatment decisions, with Prolaris quantifying prostate cancer aggressiveness and MyRisk evaluating hereditary cancer risk [3] - The integration is designed to empower patients and providers by delivering timely, precision-based insights that can lead to advanced treatment options and improved patient outcomes [3]